
Product Data Sheet

Product Name: Insulin degludec

Cat. No.: GC67998

Chemical Properties

Cas. No. 844439-96-9

Formula M.Wt

Solubility Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Background

IC50: 19.59 nM/L (insulin receptor)^[2]

Insulin degludec is an ultra-long-acting form of **insulin** used for the treatment of hyperglycemia caused by type 1 and type 2 diabetes. Insulin degludec shows binding efficiency with an **IC₅₀** value of 19.59 nM/L for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes^{[1][2]}.

Insulin degludec (0.001-1000 nM; 12 h) binds with insulin receptor with an IC₅₀ value of 19.59 nM/L^[2].

Insulin degludec (200 nM; 10 min) increases glucose uptake in HL-1 cells^[2].

Western Blot Analysis^[2]

Cell Line: HL-1 cardiomyocytes

Concentration: 200 nM

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Incubation

Time: 0-60 min

Result: Decreased the level of Akt phosphorylation after 5 and 10 min treatment.

Insulin degludec (5 U/kg; s.c. once daily for 30 days) affects glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia^[1].

Animal Model: Male Swiss mice with diabetes^[1]

Dosage: 5 U/kg

Administration: Subcutaneous injection; 5 U/kg once daily for 30 days

Result: Showed a fast response to insulin-induced hypoglycemia with a glycemic level at or slightly under 100 mg/dl after 60 min and this response effect can be abolished by cortisol. Diminished rates of glucose production and showed a low lactate production in livers. Increased the number of hepatocytes.

[1]. Bataglini C, et al. Insulin degludec and glutamine dipeptide modify glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia. J Appl Biomed. 2021 Dec;19(4):210-219.

[2]. Hartmann T, et al. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function. Cardiovasc Diabetol. 2016 Jul

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA